A5008660733- Iron Metabolism and Disorders
- Hemoglobinopathies and Related Disorders
- Blood groups and transfusion
- Erythropoietin and Anemia Treatment
- Folate and B Vitamins Research
- Erythrocyte Function and Pathophysiology
- Trace Elements in Health
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Tuberculosis Research and Epidemiology
- Blood donation and transfusion practices
- Prenatal Screening and Diagnostics
- Neonatal Health and Biochemistry
- Chronic Lymphocytic Leukemia Research
- Child Nutrition and Water Access
- Dialysis and Renal Disease Management
- Bone and Joint Diseases
- Hematological disorders and diagnostics
- Viral-associated cancers and disorders
- Pharmacological Effects and Toxicity Studies
- Renal Diseases and Glomerulopathies
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Nutrition and Health in Aging
- Multiple and Secondary Primary Cancers
Faculdade de Ciências Médicas da Santa Casa de São Paulo
2016-2025
Hospital Samaritano de São Paulo
2016-2025
Santa Casa Hospital
2010-2022
Irmandade da Santa Casa de Misericórdia de São Paulo
2006-2021
Nova Medical (United States)
2010-2016
Universidade Estadual de Campinas (UNICAMP)
2016
Palmetto Hematology Oncology
2012
Universidade Federal de São Paulo
1998-2008
HCL Technologies (India)
2002
The up-regulation of P-selectin in endothelial cells and platelets contributes to the cell–cell interactions that are involved pathogenesis vaso-occlusion sickle cell–related pain crises. safety efficacy crizanlizumab, an antibody against adhesion molecule P-selectin, were evaluated patients with cell disease.
triagem para as hemoglobinopatias (Fase 2).
Abstract The cell adhesion molecule P‐selectin plays a key role in the pathogenesis of vaso‐occlusive crisis (VOC) patients with sickle disease (SCD). In double‐blind, placebo‐controlled phase 2 SUSTAIN study, crizanlizumab (humanized, anti‐P‐selectin monoclonal antibody) 5 mg/kg significantly lowered rate VOC SCD by 45% vs placebo. SUSTAIN, were randomized to 2.5 mg/kg, or placebo intravenously 14 times over 52 weeks. primary endpoint was annual This post hoc descriptive analysis evaluated...
Although guidelines are available for hereditary hemochromatosis, a high percentage of the recommendations within them not shared between different guidelines. Our main aim is to provide an objective, simple, brief, and practical set about therapeutic aspects HFE hemochromatosis p.Cys282Tyr (C282Y/C282Y) homozygous genotype, based on published scientific studies guidelines, in form that reasonably comprehensible patients people without medical training. This final version was approved at...
This open-label, prospective, phase 2 study evaluated the safety and efficacy of deferasirox (10 ± 5 mg/kg/d) in patients with hereditary hemochromatosis (HH) iron overload refractory to or intolerant phlebotomy. Ten were enrolled all completed 12-month treatment period. There significant decreases from baseline end (i.e., 12 months) median serum ferritin (P < 0.001), mean transferrin saturation 0.05), liver concentration alanine aminotransferase 0.05). The time achieve reduction ≥50%...
Nutritional iron deficiency anemia is the most common disorder, affecting more than two billion people worldwide. Oral supplementation usually first choice for treatment of anemia, but in many conditions, oral less ideal mainly because gastrointestinal adverse events and long course needed to treat disease replenish body stores. Intravenous compounds consist an oxyhydroxide core, which surrounded by a carbohydrate shell made polymers such as dextran, sucrose or gluconate. The product...
Paroxysmal nocturnal hemoglobinuria is a chronic, multi-systemic, progressive and life-threatening disease characterized by intravascular hemolysis, thrombotic events, serious infections bone marrow failure. results from the expansion of clone hematopoietic cells that due to an inactivating mutation X-linked gene PIG-A are deficient in glycosylphosphatidylinositol-linked proteins. Early diagnosis, using flow cytometry performed on peripheral blood, gold standard test confirm diagnosis...
Blood donation results in a substantial loss of iron (200 to 250 mg) at each bleeding procedure (425 475 ml) and subsequent mobilization from body stores. Recent reports have shown that reserves generally are small depletion is more frequent blood donors than non-donors.
A hemocromatose hereditária (HH) está relacionada a diversos distúrbios do metabolismo ferro que ocasionam sua sobrecarga tecidual. HH clássica associada às mutações gene HFE (homozigose para C282Y ou duplo heterozigose C282Y/H63D), sendo encontrada quase exclusivamente em descendentes norte Europeu. hereditária, quando não ao HFE, é causada por de outros genes, recentemente identificados, envolvidos no ferro. Hepcedina o hormônio regulador inibe ferroportina, proteína exportadora dos...
Background Sickle cell disease (SCD) may cause several impacts to patients and the whole society. About 4% of population has sickle trait in Brazil, 60,000 100,000 have SCD. However, despite recognizing significant burden disease, little is known about SCD costs. Objective To estimate societal costs based on modelling, under Brazilian perspective. Methods A model was built considering perspective a one-year time horizon, including direct medical indirect (morbidity mortality). The sum life...
Sickle cell disease (SCD) is a group of hereditary chronic diseases with substantial impact on quality life and morbimortality. In Brazil, it 1 the most common diseases; however, there are sparse epidemiological data for country. Using from death certificates, we aimed to estimate median age at death, years lost because SCD, survival. From 2015 2019, identified 3320 records deaths individuals total 6 553 132 records. Among was 37 less than that general population (SCD: aged 32.0...
BACKGROUND: Animal models have shown that CD47‐deficient mice develop severe autoimmune hemolytic anemia (AIHA) because the binding of red blood cell (RBC) CD47 to signal‐regulatory protein (SIRP‐α) on macrophages contributes inhibition phagocytosis. In contrast, complement‐inhibitory proteins such as CD35, CD55, and CD59 may protect RBCs against lysis by complement. STUDY DESIGN AND METHODS: With use flow cytometric analyses, expression CD47, SIRP‐α,β peripheral monocytes 36 patients with...
Hidroxiureia (HU) constitui o avanço mais importante no tratamento de pacientes com doença falciforme (DF). Fortes evidências confirmam a eficácia da HU em adultos diminuindo os episódios dor intensa, hospitalização, número transfusões e síndrome torácica aguda. Embora evidência do crianças não seja tão forte, recentes resultados são encorajadores. Os dados atuais relação aos riscos curto longo prazos terapia aceitáveis comparado dos tratados HU. Neste artigo, apresentamos revisão detalhada...
A hemocromatose hereditária (HH) é a mais comum doença autossômica em caucasianos e caracteriza-se pelo aumento da absorção intestinal de ferro, o qual resulta acúmulo progressivo ferro no organismo. classificação HH realizada acordo com alteração genética encontrada, sendo os casos divididos tipos 1, 2A, 2B, 3 4, quando sobrecarga for associada aos genes HFE, HJV, HAMP, TFR2 SLC40A1, respectivamente. Não existem estudos brasileiros que avaliaram presença mutações relacionados à...
A anemia ferropriva permanece como uma das deficiências nutricionais mais frequentes e importantes no mundo. O tratamento com ferro deve ser iniciado preferencialmente por via oral a investigação apropriada de sua causa é obrigatória. Os autores discutem os compostos atualmente disponíveis, o perfil eficácia, segurança tolerabilidade desses medicamentos, plano terapêutico adequado possível para sucesso dessa doença tão comum importante.